Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Common Share, Disclosure: Schedule of Earnings Per Share (Tables)

3 Months Ended

Mar. 31, 2016

	For the three months ended March 31,
	2016		2015
Net loss from continuing operations	$	(131,621)	$	(492,426)
Net loss from discontinued operations		(2,004)		(152,180)
Net Loss		(133,625)		(644,606)
Basic and diluted:
Preferred stock cumulative dividend - Series D		10,705		10,589
Income applicable to preferred stockholders		10,705		10,589
Net loss applicable to common stockholders	$	(144,330)	$	(655,195)